Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

stat rx usa llc - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 180 mg - allegra-d 24 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 24 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 24 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 24 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe co

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

chanelle medical unlimited company - fexofenadine hydrochloride - film-coated tablet - 120 milligram(s) - other antihistamines for systemic use; fexofenadine

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

chanelle medical unlimited company - fexofenadine hydrochloride - film-coated tablet - 180 milligram(s) - other antihistamines for systemic use; fexofenadine

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

physicians total care, inc. - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - pioglitazone hydrochloride 15 mg - actoplus met is a thiazolidinedione and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and metformin or who have inadequate glycemic control on a thiazolidinedione alone or metformin alone. initiation of actoplus met in patients with established new york heart association (nyha) class iii or iv heart failure is contraindicated (see boxed warning ). in addition, actoplus met is contraindicated in patients with: - renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥ 1.5 mg/dl [males], ≥ 1.4 mg/dl [females], or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see warnings, metformin hydrochloride and precautions, general: metformin hydrochloride ). - known hypersensitivity to pioglitazone, metformin or any other component of actop

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

physicians total care, inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 60 mg - allegra-d 12 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 12 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 12 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 12 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe coronary arter

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

physicians total care, inc. - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 180 mg - allegra-d 24 hour extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. allegra-d 24 hour should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). allegra-d 24 hour is contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, allegra-d 24 hour is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment (see drug interactions section). it is also contraindicated in patients with severe hypertension, or severe coronary arter

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fexofenadine hydrochloride -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fexofenadine hydrochloride -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fexofenadine hydrochloride -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fexofenadine hydrochloride -